Anti-monocyte globulin in allogeneic transplantation of hematopoietic stem cells
https://doi.org/10.17650/1818-8346-2008-0-1-2-27-30
Abstract
Acute graft-versus-host disease (GFHD) and graft rejection reaction (GRR) early in the post-transplantation period are main complications of allogeneic transplantation of hematopoietic stem cells. We analyzed the incidence of principal early complications in 109 patients with various oncohematologic diseases who underwent 112 allogeneic transplantations of hematopoietic stem cells from related and unrelated donors with myeloablative and non-myeloablative regimens of conditioning with and without use of anti-monocyte globulin. Application of anti-monocyte globulin provides effective control of acute GFHD without increment of disease relapsing risk and lowers the incidence of GRR to 7%. So, results of our study showed that usage of anti-monocyte globulin with conditioning regimens for patients who habe undergone allogeneic transplantation of hematopoietic stem cells, allows to effectively decrease the incidence of early posttransplantation complications. Consequently, that increases the 4-year overall survival of these patients as compared with patients who did not undergo the use of anti-monocyte globulin.
About the Authors
Yu. R. Zalyalov
Department of bone marrow transplantation of Academician I.P.Pavlov St. Petersburg State Medical University
Russian Federation
Russian Federation
B. A. Ganapiyev
Department of bone marrow transplantation of Academician I.P.Pavlov St. Petersburg State Medical University
Russian Federation
Russian Federation
V. G. Potapenko
Department of bone marrow transplantation of Academician I.P.Pavlov St. Petersburg State Medical University
Russian Federation
Russian Federation
N. B. Mikhaylova
Department of bone marrow transplantation of Academician I.P.Pavlov St. Petersburg State Medical University
Russian Federation
Russian Federation
B. V. Afanasyev
Department of bone marrow transplantation of Academician I.P.Pavlov St. Petersburg State Medical University
Russian Federation
Russian Federation
References
1. Зубаровская Л.С., Фрегатова Л.М., Афанасьев Б.В. Трансплантация гемопоэтических стволовых клеток при гемобластозах. В кн.: Клиническая онкогематология. Под ред. М.А. Волковой. М., 2001. с. 479—94.
2. Bacigalupo A., Lamparelli T., Bruzzi P. et al. Antithymocyte globulin for graftversus-host disease prophylaxis in transplants from unrelated donors: 2 randomized studies from Gruppo Italiano Trapianti Midollo Osseo (GITMO). Blood 2001;;98(10):2942—7.
3. Dulley F.L. et al. The role of low dose busulfan (Bu) (4 mg/kg) with cyclophosphamide (Cy) as a conditioning regimen for severe aplastic anaemia (SAA). Biology of blood and marrow transplantation. 2003;9:88.
4. Finke J., Bertz H., Schmoor C. et al. Allogeneic bone marrow transplantation from unrelated donors using in vivo anti T-cell globulin. Br J Haematol 2000;11:303—13.
5. Mohty M., Bay J.-O., Faucher C. et al. Graft-versus-host disease following allogeneic transplantation from HLA-identical sibling with antithymocyte globulinbased reduced-intensity preparative regime. Blood 2003;102(2):470—6.
6. Paquette R.L., Tebyani N., Frane M. et al. Long-term outcome of aplastic anemia in adults treated with antithymocyte globulin: comparison with bone marrow transplantation. Blood 1995;85(1):283—90.
7. Remberger M. et al. Association between pretransplant Thymoglobulin and reduced non-relapse mortality rate after marrow transplantation from unrelated donors. Bone Marrow Transpl 2002;29:391—7.
8. Zander A.R., Zabelina T., Kroger N. et al. Use of a five-agent GvHD prevention regimen in recipients of unrelated donor marrow. Bone Marrow Transplant 1999;23:889—93.
Review
For citations:
Zalyalov Yu.R., Ganapiyev B.A., Potapenko V.G., Mikhaylova N.B., Afanasyev B.V. Anti-monocyte globulin in allogeneic transplantation of hematopoietic stem cells. Oncohematology. 2008;(1-2):27-30. (In Russ.) https://doi.org/10.17650/1818-8346-2008-0-1-2-27-30
Views:
198
Email this article 